Tesamorelin + Ipamorelin Blend | 13mg/3mg

Tesamorelin + Ipamorelin Blend Research Material — Buy Tesamorelin / Ipamorelin 13mg/3mg blend

This blend pairs Tesamorelin, a stabilized GHRH(1-44) analog, with Ipamorelin, a selective ghrelin receptor (GHS-R1a) agonist. As with other GHRH/GHS-R combinations, the two peptides act on independent receptor pathways that converge on pituitary somatotroph GH release, and are studied together for combined effects on the growth hormone/IGF-1 axis.

Mechanism of Action

Tesamorelin binds the GHRH receptor, stimulating Gs-coupled cAMP/PKA signaling and GH release from somatotrophs, with a stabilized structure that resists enzymatic degradation relative to native GHRH. Ipamorelin binds GHS-R1a, coupling to Gq/11 to mobilize intracellular calcium via a separate signaling arm, with high selectivity for GH release over ACTH, cortisol, and prolactin. The combination is studied for its effect on GH pulse amplitude when both receptor pathways are engaged concurrently.

Research Applications

• Combined GHRH-receptor / GHS-R1a secretagogue research
• Visceral fat and body-composition research models
• IGF-1 axis and hepatic signaling studies
• Growth hormone pulse amplitude and pulsatility research
• Comparative secretagogue combination studies

Specifications

• Components: Tesamorelin + Ipamorelin
• CAS Numbers: Tesamorelin 218949-48-5; Ipamorelin 170851-70-4
• Ipamorelin Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
• Purity: ≥97% (HPLC verified, each component)
• Form: Lyophilized powder blend
• Available Size: 13mg / 3mg (Tesamorelin / Ipamorelin)

Storage & Handling

Store lyophilized blend at −20°C, protected from light and moisture. Once reconstituted with bacteriostatic water, store at 4°C and use within 28 days. All handling should be performed under sterile laboratory conditions by trained research personnel.

For in-vitro laboratory research use only. Not for human or animal consumption. Not a drug, supplement, or medicinal product.